Sanofi Pays $650M for Protein Sciences and its Flu Vaccine

Jul 11, 2017

Sanofi announced it will purchase Protein Sciences, a vaccines biotechnology company located in Meriden, Connecticut. Sanofi will make an upfront payment of $650 million and pay up to $100 million for certain milestones.

Protein Sciences received approval from the U.S. Food and Drug Administration in October 2016 for their Flublok Quadrivalent Influenza Vaccine (QIV). According to the companies, Flublok is the only recombinant protein-based influenza vaccine approved by the FDA.

“The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine,” said David Loew, Sanofi executive vice president and Head of Sanofi Pasteur, Sanofi’s vaccines division.

The acquisition is expected to close in the third quarter of 2017, subject to customary regulatory approvals.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments